Dr. Ali Explains Misconceptions About Biosimilars

Haythem Y. Ali, MD
Published: Thursday, May 24, 2018



Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

A biosimilar is defined by the FDA as a biological product that is highly similar to an existing FDA-approved reference product, and has no meaningful differences. Since biosimilars are relatively new to the cancer sphere in the United States, Ali says that some providers are unsure of the differences between biosimilars and generic drugs.

Ali says that the only way for providers to understand biosimilars, and therefore become comfortable with their use, is through education. There are a different set of rules to follow to get a biosimilar approved by the FDA, and providers should understand those rules and their importance, Ali explains.

Although there have been multiple approvals of biosimilars as cancer treatment in the United States, they are not yet available. But there are supportive care biosimilars in oncology for the myeloid growth factors GCSF, or filgrastim (Neupogen).
SELECTED
LANGUAGE


Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

A biosimilar is defined by the FDA as a biological product that is highly similar to an existing FDA-approved reference product, and has no meaningful differences. Since biosimilars are relatively new to the cancer sphere in the United States, Ali says that some providers are unsure of the differences between biosimilars and generic drugs.

Ali says that the only way for providers to understand biosimilars, and therefore become comfortable with their use, is through education. There are a different set of rules to follow to get a biosimilar approved by the FDA, and providers should understand those rules and their importance, Ali explains.

Although there have been multiple approvals of biosimilars as cancer treatment in the United States, they are not yet available. But there are supportive care biosimilars in oncology for the myeloid growth factors GCSF, or filgrastim (Neupogen).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x